CSC Financial: In the first three quarters of 2026, the operating performance of the pharmaceutical sector continued to improve, and the trend is expected to continue in 2027.

CSC Financial research report notes that the pharmaceutical sector's operations continued to improve in the first three quarters of 2026, and the trend is expected to extend into 2027. Looking ahead to 2027, innovative drugs' overseas clinical trials and registrations will enter a validation period; with increased overseas expansion and the rise of strategic alliances, companies will face a larger market and a more complex competitive environment, with both opportunities and risks. CXO order conversion and recovering upstream demand will reinforce each other, and AIDD will further drive demand upward. Device performance inflection points are gradually emerging; for traditional Chinese medicine and pharmaceutical distribution, focus on operational recovery; for blood products and vaccines, focus on new products, consolidation, and overseas expansion. It is recommended to seize opportunities around innovation and internationalization, while also increasing attention to the main line of marginal improvement.